Clasp Therapeutics launches with $150 million in hand

GO BACK TO PRESS RELEASES & MEDIA Chemical & Engineering News March 20, 2024 Clasp Therapeutics launches with $150 million in hand Backed by Third Rock Ventures, Novo Holdings, and Catalio Capital Management, the company bets on improving an emerging anticancer modality Clasp Therapeutics , a company that aims to create a next-generation version of immunoncology drugs called bispecific T cell engagers (TCEs), launched today with $150 million in series A financing. The company’s platform, based on the work of cancer geneticist Bert Vogelstein and immune-oncologist Drew Pardoll at Johns Hopkins